scholarly article by Kevin W Garey et al published 23 October 2019 in Open Forum Infectious Diseases
Attributes | Values |
---|
rdf:type
| |
description
| - wetenschappelijk artikel (nl)
- article scientifique publié en 2019 (fr)
- im Oktober 2019 veröffentlichter wissenschaftlicher Artikel (de)
- наукова стаття, опублікована в жовтні 2019 (uk)
- scholarly article by Kevin W Garey et al published 23 October 2019 in Open Forum Infectious Diseases (en)
|
publication date
| |
publication date
| |
author name string
| |
author name string
| - Michael Silverman
- Julie Mercier
- Murray Ducharme
- M Jahangir Alam
- Kevin W Garey
- Anne J Gonzales-Luna
- Martin Kankam
- Corinne Seng Yue
|
rdfs:label
| - LB7. A Randomized, Blinded, Placebo- and Vancomycin-Controlled, First-In-Human (FIH) Study of the Safety, Pharmacokinetics (PK), and Fecal Microbiome Effects of ACX-362E, a Novel Anti-Clostridial DNA Polymerase IIIC (polIIIC) Inhibitor (en)
- LB7. A Randomized, Blinded, Placebo- and Vancomycin-Controlled, First-In-Human (FIH) Study of the Safety, Pharmacokinetics (PK), and Fecal Microbiome Effects of ACX-362E, a Novel Anti-Clostridial DNA Polymerase IIIC (polIIIC) Inhibitor (nl)
|
skos:prefLabel
| - LB7. A Randomized, Blinded, Placebo- and Vancomycin-Controlled, First-In-Human (FIH) Study of the Safety, Pharmacokinetics (PK), and Fecal Microbiome Effects of ACX-362E, a Novel Anti-Clostridial DNA Polymerase IIIC (polIIIC) Inhibitor (en)
- LB7. A Randomized, Blinded, Placebo- and Vancomycin-Controlled, First-In-Human (FIH) Study of the Safety, Pharmacokinetics (PK), and Fecal Microbiome Effects of ACX-362E, a Novel Anti-Clostridial DNA Polymerase IIIC (polIIIC) Inhibitor (nl)
|
name
| - LB7. A Randomized, Blinded, Placebo- and Vancomycin-Controlled, First-In-Human (FIH) Study of the Safety, Pharmacokinetics (PK), and Fecal Microbiome Effects of ACX-362E, a Novel Anti-Clostridial DNA Polymerase IIIC (polIIIC) Inhibitor (en)
- LB7. A Randomized, Blinded, Placebo- and Vancomycin-Controlled, First-In-Human (FIH) Study of the Safety, Pharmacokinetics (PK), and Fecal Microbiome Effects of ACX-362E, a Novel Anti-Clostridial DNA Polymerase IIIC (polIIIC) Inhibitor (nl)
|
author
| |
author
| |
title
| |
title
| - LB7. A Randomized, Blinded, Placebo- and Vancomycin-Controlled, First-In-Human (FIH) Study of the Safety, Pharmacokinetics (PK), and Fecal Microbiome Effects of ACX-362E, a Novel Anti-Clostridial DNA Polymerase IIIC (polIIIC) Inhibitor (en)
|
page(s)
| |
page(s)
| |
instance of
| |
instance of
| |
main subject
| |
main subject
| |
published in
| |
published in
| |
issue
| |
volume
| |
issue
| |
volume
| |
DOI
| |
DOI
| |
DOI
| |
copyright license
| |
copyright status
| |
copyright license
| |
copyright status
| |
PMCID
| |
PMCID
| |
is about
of | |
is cites work
of | |
is cites work
of | |